Announcement of The Consolidated Financial Report for The 3rd Quarter of 2022
2022.11.4
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2022/11/04 | Time of announcement | 17:20:33 |
| Subject | Announcement of The Consolidated Financial Report for The 3rd Quarter of 2022 | ||||
| Date of events | 2022/11/04 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2022/11/04 2.Date of the audit committee approved:2022/11/04 3.Start and end dates of financial reports or unaudited finaicial information of the reporting period:2022/01/01~2022/09/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):3,528,806 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):2,197,217 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):913,306 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):1,075,254 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):865,003 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):849,717 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):3.42 11.Total assets end of the period (thousand NTD):9,836,854 12.Total liabilities end of the period (thousand NTD):3,790,921 13.Equity attributable to owners of parent end of the period (thousand NTD):5,463,648 14.Any other matters that need to be specified:None |
||||